Kamada Ltd. (NASDAQ: KMDA) announced a 17% increase in revenue to $44.0 million and a 54% surge in Adjusted EBITDA to $11.6 million for the first quarter of 2025, compared to the previous year. This growth is attributed to strong sales of GLASSIA® and KAMRAB® in non-U.S. markets, alongside contributions from VARIZIG® and royalty income from GLASSIA, products addressing critical health needs such as emphysema, Rabies disease prevention, and varicella disease post-exposure prophylaxis.
The company's gross margins improved to 47%, up from 44%, reflecting a favorable product mix. Kamada has reiterated its full-year guidance, expecting total revenue between $178 million and $182 million and adjusted EBITDA of $38 million to $42 million.
Key achievements in the quarter include the initiation of a post-marketing research program for CYTOGAM® to improve CMV disease management and the expansion of plasma collection operations with a new center in San Antonio, Texas, projected to add $8 million to $10 million in annual revenue at full capacity. Additionally, Kamada secured a deal to supply KAMRAB and VARIZIG in Latin America through 2027, expected to generate around $25 million in revenue. The company is also making progress on the InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin therapy, with an interim futility analysis planned by the end of 2025.
Kamada's strategic initiatives in organic growth, business development, plasma collection, and clinical research underscore its commitment to advancing in the biopharmaceutical industry.
